GLP-1s have recently soared in popularity as new weight loss alternatives. Originally created to treat diabetes, these drugs – including Ozempic, Wegovy, and Mounjaro – have been found to suppress appetites and induce substantial weight loss in many patients. Extensive media coverage and celebrity endorsements have only heightened demand. Using real-time data, Truveta analyzed trends in first-time GLP-1 prescriptions.
